Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Image credit: Inna Dodor - stock.adobe.com
Interchangeable Insulin and Medicaid1
A poster examining the impact of the first interchangeable biosimilar for insulin glargine on spending and utilization of state Medicaid programs found the interchangeability label helped reverse a declining market share for insulin glargine biosimilars, helping to generate significant savings for the programs.
However, the researchers noted that utilization of biosimilars varied widely across states, suggesting the need for more biosimilar education and financial incentives to promote their adoption. Additionally, 4 states, and Puerto Rico, completely restrict interchangeability.
The first interchangeable insulin glargine biosimilar (Semglee) became available to Americans in July 2021.
In the study, the researchers extracted Medicaid State Drug Utilization Data for all insulin glargine products between 2020 and 2022. The reference products for the study were Lantus and Toujeo, and the biosimilars were Semglee, Basaglar, and unbranded insulin glargine-yfgn.
Results showed that the biosimilars had 48% market share by Q1 2020, presenting with a downward trend of 2.2% per quarter as patients switched to reference products (P < .01). Following the introduction of an interchangeable option, the trend reversed, with biosimilar market share growing by 2.8% per quarter (P < .01).
Market entry of an interchangeable biosimilar generated $60.6 million for Medicaid programs between Q4 2021 and Q4 2022. The use of interchangeable biosimilars across Medicaid plans ranged from 0% to 93% in quarterly market share (mean [SD], 9.1% [17.9%]). Six states reported no use of the biosimilar.
Factors Driving Biosimilar Access2
A poster from Precision Value & Health evaluated the top factors driving access to biosimilars. The study was conducted in response to slow uptake rates for several biosimilar categories, such as infliximab and ranibizumab, in the US.
In October 2023, the researchers conducted a survey among health plan stakeholders recruited from a database of market-access decision-makers. Twenty-five people responded to the survey.
Results showed that a majority of respondents preferred a low wholesale acquisition cost (WAC), low-rebate strategy over a high-WAC, high-rebate strategy for new biosimilar contracting (84% vs 16%). Additionally, 64% said they were likely to restrict a biosimilar covered under the pharmacy benefit (infliximab, insulins, and adalimumab) compared with the medical benefit (rituximab, ranibizumab, pegfilgrastim, bevacizumab, filgrastim).
When asked about indications that yield the best access restrictions for biosimilars compared with their reference products, cancer indications and pediatric indications were the most reported (32% each). When considering market factors, a pharmacy benefit manager contract for the reference product was cited as the most likely reason for restrictions for biosimilars (36%). The authors speculated as reference product shares are expected to decline, the impact of these factors may weaken in the future.
Although 96% of respondents reported being confident in switching from a reference product to a biosimilar, the operational barrier that was most to blame for restricted access to biosimilars was the need for pharmacies to contact prescribers for a biosimilar (44%), supporting the idea that interchangeable designations could improve patient access to these lower-cost biologics.
References
1. Devine J, Hanson K, Lim D. The impact of interchangeability on biosimilar insulin glargine use and spending in Medicaid. Presented at: AMCP 2024; April 15-18, 2024; New Orleans, LA. Poster E2.
2. Terrone CJ, Danielson D, Miller C. Factors driving biosimilar access among US health plans. Presented at: AMCP 2024; April 15-18, 2024; New Orleans, LA. Poster U13.
Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow
May 6th 2025Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of noncommunicable diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
FDA's Expanded Access: From Laetrile to Right to Try, Ethical Debates Over Early Drug Access
April 28th 2025Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA approval, highlighting the crucial role of clinical trials and ethical safeguards at the 2025 Festival of Biologics USA.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Unlocking Biosimilar Potential in Specialty Pharmacies With Legislative Support, Formulary Changes
April 24th 2025Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of biosimilar adoption, which has significant cost saving potential in the next decade.
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.